Proactiveinvestors USA & Canada Emerald Health Therapeutics Inc https://ca.proactiveinvestors.com Proactiveinvestors USA & Canada Emerald Health Therapeutics Inc RSS feed en Sat, 20 Jul 2019 07:52:05 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[Media files - Emerald Health Therapeutics' JV acquires second greenhouse, potentially doubling production capacity ]]> https://ca.proactiveinvestors.com/companies/stocktube/12856/emerald-health-therapeutics--jv-acquires-second-greenhouse-potentially-doubling-production-capacity-12856.html Wed, 03 Apr 2019 11:42:00 -0400 https://ca.proactiveinvestors.com/companies/stocktube/12856/emerald-health-therapeutics--jv-acquires-second-greenhouse-potentially-doubling-production-capacity-12856.html <![CDATA[News - Emerald Health's subsidiary Verdélite Sciences settles sale litigation ]]> https://ca.proactiveinvestors.com/companies/news/213626/emerald-health-s-subsidiary-verdlite-sciences-settles-sale-litigation-213626.html Cannabis company Emerald Health Therapeutics Inc (CVE:EMH) (OTCQX:EMHTF) announced Wednesday that its subsidiary Verdélite Sciences Inc has settled all legal claims made against it by Pivot Pharmaceuticals Inc.

The claims related to a non-binding letter of intent which Verdélite and its former shareholders had previously entered into with Pivot with respect to a potential sale of Verdélite.

READ: Emerald Health Therapeutics completes setting up of Emerald Health Naturals joint venture

Thanks to the settlement, all claims against Verdélite have been discharged without Verdélite making any payment or providing compensation to Pivot.

Vancouver-based Emerald Health is a licensed producer of cannabis. Its Verdélite operation in Quebec runs a 75,000 square feet indoor cannabis cultivation facility in St. Eustache, Quebec.

Emerald Health shares closed up 3.3% to hit C$3.45 on Tuesday.

Contact Ellen Kelleher at ellen@proactiveinvestors.com

]]>
Wed, 30 Jan 2019 08:34:00 -0500 https://ca.proactiveinvestors.com/companies/news/213626/emerald-health-s-subsidiary-verdlite-sciences-settles-sale-litigation-213626.html
<![CDATA[News - Emerald Health Therapeutics completes setting up of Emerald Health Naturals joint venture ]]> https://ca.proactiveinvestors.com/companies/news/212328/emerald-health-therapeutics-completes-setting-up-of-emerald-health-naturals-joint-venture-212328.html Vancouver-based cannabis company Emerald Health Therapeutics Inc’s (CVE:EMH) (OTCQX:EMHTF) announced Thursday that it has completed the setting up of Emerald Health Naturals, its 51:49 joint venture with San Diego-based Emerald Health Bioceuticals.

Emerald Health Therapeutics has invested C$5 million for a 51% equity ownership of Emerald Health Naturals while Emerald Health Bioceuticals granted exclusive Canadian distribution rights to its product line in exchange for a 49% equity stake in the joint venture.

READ: Emerald Health Therapeutics receives Health Canada licenses for its natural products line

Emerald Health Bioceutical’s product line consists of nutritional supplements that use non-cannabis, non-psychoactive plant-based bioactive compounds to support the body’s endocannabinoid system.

The products, including Endo Sleep, Endo Inflame, Endo Brain, Endo Bliss and Endo Calm, were designed to treat stress, anxiety, restless sleep, pain and other conditions using non-cannabis ingredients.

“We have the unique opportunity to brand Emerald through Emerald Health Naturals offering of the Endo product line through a number of valuable sales channels that are frequently visited by cannabis users but which cannot currently sell cannabis products,” Executive Chairman Avtar Dhillon told Proactive Investors.

Emerald Health is a licensed producer authorized by Health Canada to grow, sell and produce cannabis across the country.

Emerald also recently strengthened its intellectual property portfolio via a partnership with the cannabis-focused research facility VivaCell Biotechnologies. The institute will work with Emerald Health to evaluate formulas and determine consistent dosages as the company continues to develop medical and recreational cannabis products.

 

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive 

]]>
Thu, 10 Jan 2019 07:40:00 -0500 https://ca.proactiveinvestors.com/companies/news/212328/emerald-health-therapeutics-completes-setting-up-of-emerald-health-naturals-joint-venture-212328.html
<![CDATA[News - Emerald Health Therapeutics receives Health Canada licenses for its natural products line ]]> https://ca.proactiveinvestors.com/companies/news/210509/emerald-health-therapeutics-receives-health-canada-licenses-for-its-natural-products-line-210509.html Cannabis company Emerald Health Therapeutics Inc’s (CVE:EMH) (OTCQX:EMHTF) joint venture, Emerald Health Naturals has received products licenses and natural products numbers from Health Canada for its Endo product line.

The line of nutritional products was developed by Emerald Health Bioceuticals Inc alongside its scientific advisors.

READ: Level Brands shares soar after deal to buy CBD brand cbdMD

The products, including Endo Sleep, Endo Inflame, Endo Brain, Endo Bliss and Endo Calm, were designed to treat stress, anxiety, restless sleep, pain and other conditions using non-cannabis ingredients.

“We have the unique opportunity to brand Emerald through EHN’s offering of the Endo product line through a number of valuable sales channels that are frequently visited by cannabis users but which cannot currently sell cannabis products,” said Executive Chairman Avtar Dhillon.

The line is expected to launch in mid-2019 and will be available in natural health stores, grocery stores and pharmacies.

Dhillon said that Emerald will be well-positioned to add cannabinoid compounds to Endo products if CBD and other non-psychoactive cannabinoid products are allowed to be sold via these channels going forward.

While recreational marijuana has been legalized in Canada, the legality of CBD is still in question.

Shares of Emerald Health were down about 6% to US$2.02 in Tuesday Morning trading.

 

Contact Lenore Fedow at lenore@proactiveinvestors.com

Follow her on Twitter: @LenoreMariee

]]>
Tue, 04 Dec 2018 10:56:00 -0500 https://ca.proactiveinvestors.com/companies/news/210509/emerald-health-therapeutics-receives-health-canada-licenses-for-its-natural-products-line-210509.html
<![CDATA[News - Emerald Health Therapeutics' joint venture receives TSX Venture Exchange conditional approval ]]> https://ca.proactiveinvestors.com/companies/news/209504/emerald-health-therapeutics-joint-venture-receives-tsx-venture-exchange-conditional-approval-209504.html Emerald Health Therapeutics Inc (CVE:EMH, OTCMKTS:EMHTF) said Monday that it has received conditional approval from the TSX Venture Exchange for its joint venture with San Diego-based Emerald Health Bioceuticals (EHB).

Vancouver-based Emerald Health Therapeutics will invest C$5 million for a 51% equity stake in the joint venture, known as Emerald Health Naturals.

READ: Emerald Health Therapeutics files 17 US patent applications to protect product line

EHB will grant the joint venture exclusive Canadian distribution rights to its product line in exchange for 49% equity ownership. EHB’s products consist of nutritional supplements that use non-cannabis, non-psychoactive plant-based bioactive compounds to support the body’s endocannabinoid system of neurotransmitters that bind to cannabinoid receptors.

Market research commissioned by Emerald Health Therapeutics has found that about 60% of legal cannabis users also use natural health products.

Shares of Emerald Health Therapeutics slipped C$0.18 to C$3.74 in Canada. They slipped US$0.16 to US$2.84 in OTC trading.


Contact Dennis Fitzgerald at dennis@proactiveinvestors.com
 

]]>
Mon, 19 Nov 2018 15:08:00 -0500 https://ca.proactiveinvestors.com/companies/news/209504/emerald-health-therapeutics-joint-venture-receives-tsx-venture-exchange-conditional-approval-209504.html
<![CDATA[News - Canadian cannabis company Emerald Health Therapeutics files 17 US patent applications to protect product line ]]> https://ca.proactiveinvestors.com/companies/news/207183/canadian-cannabis-company-emerald-health-therapeutics-files-17-us-patent-applications-to-protect-product-line-207183.html The cannabis company Emerald Health Therapeutics Inc (CVE:EMH, OTCQX:EMHTF) has filed 17 US patent applications to protect its array of Defined Dose cannabis dosage forms and formulations.

The new patent applications contribute to Emerald’s intellectual property portfolio and advance its efforts to develop distinctive cannabis products for medical use as well as recreational purposes.

Although cannabis is not legal at the federal level in the US, it is considered an important “first to file” jurisdiction for intellectual property pertaining to cannabis and cannabinoids. The Patent Cooperation Treaty permits Emerald to file Canadian and international versions of these US patent applications in 152 countries over the coming year.

The 17 patent applications relate to inhaled dosage forms for smoking as well as vaping and also cover capsule and edible cannabis.

READ: Emerald Health Therapeutics partners with cannabis researcher VivaCell to boost patent portfolio

Emerald Health is a licensed producer authorized by Health Canada to grow, sell and produce cannabis across the country.

A number of the Defined Dose cannabis products are already eligible for launch in Canada as the country is set to legalize recreational marijuana, starting tomorrow. But other products are set to be eligible following regulatory changes next year.

“We expect significant potential cannabis market growth by offering adult users and medical consumers consistent product characteristics, dosing regimens, and alternative methods of consumption, with safety-enhanced through GMP-compliant production and enhance product utility achieved through knowledge of science,” said CEO Emerald Chris Wagner. “Emerald’s filing of these patent applications is an important step.”

Emerald also recently strengthened its intellectual property portfolio via a partnership with the cannabis-focused research facility VivaCell Biotechnologies. The institute will work with Emerald Health to evaluate formulas and determine consistent dosages as the company continues to develop medical and recreational cannabis products.

Emerald Health closed up 4.7% to hit $3.92 on Monday.

Contact Ellen Kelleher at ellen@proactiveinvestors.com

]]>
Tue, 16 Oct 2018 08:19:00 -0400 https://ca.proactiveinvestors.com/companies/news/207183/canadian-cannabis-company-emerald-health-therapeutics-files-17-us-patent-applications-to-protect-product-line-207183.html
<![CDATA[News - Emerald Health Therapeutics partners with cannabis researcher VivaCell to boost patent portfolio ]]> https://ca.proactiveinvestors.com/companies/news/206302/emerald-health-therapeutics-partners-with-cannabis-researcher-vivacell-to-boost-patent-portfolio-206302.html Cannabis company Emerald Health Therapeutics Inc (CVE:EMH, OTCQX:EMHTF) is looking to strengthen its intellectual property portfolio via a partnership with cannabis-focused research facility VivaCell Biotechnologies.

The institute will work with Emerald Health, evaluating formulas and determining consistent dosages as the company continues to develop medical and recreational cannabis products.

READ: Emerald Health Therapeutics secures long-term supply of hemp for CBD extraction

Emerald Health is a licensed producer authorized by Health Canada to grow, sell and produce cannabis across the country.

“There are a rare few organizations that focus their understanding of the cannabis plant at the heart of its scientific development and strategic operations,” said Emerald CEO Chris Wagner.

The institute partners with academic research centers in Spain like the University of Córdoba, Complutense University of Madrid, Instituto Cajal in Madrid as well as Italy's University of Piemonte Orientale.

The company currently holds 17 patents filed and hopes the data stemming from this partnership will translate into more in the future.

“Our goal is to expand our product pipeline with innovative products substantiated by scientific data and protected by our intellectual property,” added Wagner.

VivaCell is a wholly-owned subsidiary of Emerald Health Sciences, which has a 32% stake in Emerald Health Therapeutics Inc.

Shares of Emerald Health were up slightly to $3.89 by the closing bell Tuesday.

]]>
Wed, 03 Oct 2018 08:38:00 -0400 https://ca.proactiveinvestors.com/companies/news/206302/emerald-health-therapeutics-partners-with-cannabis-researcher-vivacell-to-boost-patent-portfolio-206302.html
<![CDATA[News - Emerald Health Therapeutics secures long-term supply of hemp for CBD extraction ]]> https://ca.proactiveinvestors.com/companies/news/205774/emerald-health-therapeutics-secures-long-term-supply-of-hemp-for-cbd-extraction-205774.html Emerald Health Therapeutics Inc (CVE:EMH, OTCQX:EMHTF) announced Wednesday that it had secured a long-term supply of hemp from Emerald Health Hemp Inc for extraction into CBD oil.

The Canadian company is a licensed producer authorized by Health Canada to grow, sell and produce cannabis across the country.

It has signed a deal with Emerald Health Hemp to purchase nearly 500 acres of chaff in 2018, and around 1,000 acres from 2019 to 2022, with an option to renew the deal for two additional years. Emerald Health Hemp is a wholly owned subsidiary of Emerald Health Sciences, which owns approximately 32% of the shares of Emerald Health Therapeutics Inc.

The long-term supply of hemp chaff secured by Emerald Health Therapeutics will be processed with the expertise of Factors R&D Technologies, a division of the Factors Group of Nutritional Companies, with whom Emerald Health Therapeutics.

The stock dipped about 2% to C$4.73 in morning trading in Toronto.

READ: Redfund Capital reckons portfolio firm Biolog Inc is "on the cusp" of greatness

In this exclusive arrangement, Factors R&D will provide Emerald pharmaceutical-grade, industrial-scale manufacturing capacity as well as expertise in extraction, softgel production, and packaging focused on the rapidly emerging market opportunities for medicinal cannabis in Canada and internationally. This collaboration leverages the Factors Group’s decades of experience in product development, formulation and innovation.

With the legalization of recreational marijuana in Canada on October 17, farmers will be able to sell hemp chaff to licensed processors.

“We see non-smoked, non-psychoactive CBD consumption as a major growth opportunity in both the medical and adult-use market in Canada, and our Factors Group alliance uniquely positions us with the largest biomass extraction and softgel encapsulation facility in Canada to produce value-added products to serve this market,” Chris Wagner, CEO of Emerald Health Therapeutics said in a statement.

“Our intent is to secure significant low-cost cannabinoid supply to serve all our manufacturing and marketing goals and hemp is expected to be our lowest cost source of CBD. We are very pleased with the rapid advancement of our Pure Sunfarms production joint venture with Village Farms and our St. Eustache facility in Quebec. Our collaboration with Emerald Health Hemp now expands our ability to produce CBD products,” he added.

Emerald Health Hemp has established agreements to purchase approximately 500 acres of harvested hemp chaff, plant material consisting mainly of flower and leaf in Manitoba and Prince Edward Island in 2018, with a plan to expand field operations in 2019.

“Canada is one of the largest producers of hemp in the world and with Bill C-45 the value of hemp will continue to grow,” said Prince Edward Island Minister of Agriculture and Fisheries Robert L. Henderson. “I am pleased that farmers in Prince Edward Island are embracing the commercial opportunities that this plant brings to the region with the investment and assistance of businesses like Emerald.” 

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive 

]]>
Wed, 26 Sep 2018 09:41:00 -0400 https://ca.proactiveinvestors.com/companies/news/205774/emerald-health-therapeutics-secures-long-term-supply-of-hemp-for-cbd-extraction-205774.html
<![CDATA[Media files - Emerald Health Therapeutics CFO confirms Canadian supply deals, calls US market 'tantalizing' ]]> https://ca.proactiveinvestors.com/companies/stocktube/10467/emerald-health-therapeutics-cfo-confirms-canadian-supply-deals-calls-us-market-tantalizing--10467.html Thu, 13 Sep 2018 15:36:00 -0400 https://ca.proactiveinvestors.com/companies/stocktube/10467/emerald-health-therapeutics-cfo-confirms-canadian-supply-deals-calls-us-market-tantalizing--10467.html <![CDATA[Media files - Emerald Health Therapeutics updates company changing partnership ]]> https://ca.proactiveinvestors.com/companies/stocktube/10307/emerald-health-therapeutics-updates-company-changing-partnership-10307.html Fri, 31 Aug 2018 15:29:00 -0400 https://ca.proactiveinvestors.com/companies/stocktube/10307/emerald-health-therapeutics-updates-company-changing-partnership-10307.html <![CDATA[Media files - Emerald Health Therapeutics 'on the cutting edge' of new cannabis market ]]> https://ca.proactiveinvestors.com/companies/stocktube/9783/emerald-health-therapeutics-on-the-cutting-edge-of-new-cannabis-market-9783.html Thu, 05 Jul 2018 14:27:00 -0400 https://ca.proactiveinvestors.com/companies/stocktube/9783/emerald-health-therapeutics-on-the-cutting-edge-of-new-cannabis-market-9783.html <![CDATA[News - Emerald Health Therapeutics expands relationship with VANC Pharmaceuticals ]]> https://ca.proactiveinvestors.com/companies/news/195186/emerald-health-therapeutics-expands-relationship-with-vanc-pharmaceuticals-195186.html Cannabis producer Emerald Health Therapeutics Inc (CVE:EMH, OTCQX:EMHTF) has expanded its relationship with VANC Pharmaceuticals Inc (CVE:VANC) via agreements, allowing it to sell medicinal cannabis through pharmacies.

As well as the supply deals, there is an investment and VANC has issued to Emerald’s affiliate warrants to acquire over 3mln VANC shares at 33 cents each for two years.

WATCH: Emerald Health Therapeutics 'on the cutting edge' of new cannabis market

VANC was granted rights to sell and distribute certain of the group's endocannabinoid-supporting products in Canada to licenced pharmacies and the pair will work together to distribute medical cannabis to Canadian pharmacies if pharmacies become authorised to do so by Health Canada.

"Our goal is to be strongly positioned to sell medicinal cannabis through pharmacies," said Avtar Dhillon, the managing director and executive chairman at Emerald.

"With VANC’s existing and developing agreements with pharmaceutical wholesalers, a national sales force, and relationships with key pharmacy chain decisionmakers and stakeholders, VANC would be well-prepared to achieve penetration for Emerald products.

“As a starting point, we look forward to VANC’s assistance in helping us introduce Emerald’s non-cannabis product line into this channel. We also believe our investment will benefit from VANC’s growth potential with its unique and expanding product line that allow pharmacies to create new clinical pharmacy services.”

Bob Rai, chief executive at VANC said: "Pharmacies provide a safe and trusted place to purchase medicine, while also offering expert advice regarding the use of medicines.

"They are the ideal channel for the distribution of medicinal cannabis."

Emerald Health shares  in Toronto eased 1.18% to C$5.03.

]]>
Tue, 17 Apr 2018 10:15:00 -0400 https://ca.proactiveinvestors.com/companies/news/195186/emerald-health-therapeutics-expands-relationship-with-vanc-pharmaceuticals-195186.html